Allergy

Ongoing Projects

Sponsor Protocol Code Trial Name Principal Investigator Phase Therapeutic Area Diseases and Conditions
GSK 206867 A Phase 3, 24-week, randomized, double-blind, parallel-group Bayesian Dynamic Borrowing study comparing the efficacy, safety, tolerability and pharmacokinetics of FF/UMEC/VI with FF/VI in 12-17-year-old participants with inadequately controlled asthma on stable maintenance therapy with ICS/LABA CANSIN SAÇKESEN (Prof.Dr.) Phase 3 Pediatric Allergy and Immunologic Diseases Asthma Disease